EQUITY RESEARCH MEMO

Actimus Bio

Generated 5/24/2026

Executive Summary

Conviction (model self-assessment)60/100

Actimus Bio, established in 2005 and headquartered in Visakhapatnam, India, is a contract research organization (CRO) providing end-to-end services for pharmaceutical and biotech companies. Its offerings span bioanalytical testing, bioavailability/bioequivalence (BA/BE) studies, biopharmaceutics, clinical trial management, medical writing, and statistical analysis. Leveraging FDA-approved, state-of-the-art facilities and a multidisciplinary team of 200–500 employees, Actimus supports drug development across multiple therapeutic areas. As a privately held platform company, Actimus does not develop its own drugs but rather enables sponsors to accelerate development timelines through reliable, cost-effective outsourcing solutions. The firm has built a reputation over two decades as a trusted partner in the global CRO market, particularly for sponsors seeking high quality at competitive rates from an established Asian provider.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)